Metformin (available under trade names such as Glucophage, Glumetza, and Fortamet) may also reduce the risk of age-related macular degeneration (AMD), a significant cause of visual loss in persons aged 50 and older, according to new study. The researchers noted that although more studies are needed to confirm these findings, the data so far suggest that patients using metformin should be informed about the potential reduction in their risk of developing AMD.
AMD is the most common form of blindness in people older than 75. It's estimated to affect millions of people worldwide. About half of those who get AMD suffer serious consequences such as blindness. The other half have less severe symptoms that do not interfere with their daily lives but which can include blurry vision or blind spots in their field of view.
People who take insulin or hypoglycemic drugs such as sulfonylureas or meglitinides are at increased risk of developing vision problems because these medications increase blood glucose levels. As high blood glucose levels contribute to the development of several complications, including nephropathy (a disease of the kidneys), neuropathy (nerve damage), and retinopathy (eye damage), patients taking these medications should be made aware of the risk.
In recent years, researchers have begun to investigate the relationship between diabetes and AMD.
(NaturalNews) — The date is March 23, 2020. Metformin, a common type 2 diabetic medication, may have an unexpected but good side effect. According to new research, those who take the medicine tend to have considerably slower decreases in thinking and memory as they age.
The study was published online February 4 in JAMA Internal Medicine. It showed that among people over the age of 50, those who took metformin were 31 percent less likely to be diagnosed with dementia over the following two years compared to those who did not take the drug. This advantage disappeared by about four years after starting the medication.
"These findings suggest that although further studies are needed to confirm these results, patients should not assume that taking metformin will necessarily lead to a worsening of their cognitive abilities," said senior researcher Dr. Leonardo Ferreira, from the University of North Carolina School of Medicine. "Rather, it may actually protect against developing dementia."
Dr. Ferreira noted that while this study showed a reduced risk of dementia for people on metformin, it cannot say whether or not the medication caused the difference observed. However, he added that since most cases of dementia are due to Alzheimer's disease, which is characterized by brain cell death, this study does show that metformin may help prevent this type of cell death.
Metformin is a common diabetes therapy that has been demonstrated to stimulate the synthesis of recognized longevity-promoting signaling molecules in cells. /span>
Studies have shown that people with type 2 diabetes are at increased risk for dementia and other cognitive problems. Taking insulin or oral medications used to control blood sugar levels may worsen these conditions. Metformin appears to protect against cognitive decline in people with diabetes, independent of its effect on blood sugar levels.
Research conducted by scientists at the University of Texas Medical Branch found that mice given metformin lived longer than normal mice. In addition, mice transplanted with fat tissue containing human genes related to metabolism had reduced risks of developing diseases such as cancer and diabetes when they were given metformin along with their transplants. The study findings were published in January 2013 in the journal Cell.
Another study conducted by researchers at the Harvard School of Public Health found that older adults who took metformin were less likely to suffer from dementia later in life. The study included more than 14,000 people over the age of 70 who were not diagnosed with dementia when the survey began. Those who used metformin were 30 percent less likely to develop dementia during the follow-up period compared to those who did not take the drug.
Metformin has been demonstrated to increase insulin sensitivity and slow muscle loss in insulin-resistant adults via a mechanism that may include ceramide production. ... Metformin's Impact on Muscle Health in Older Adults
|Official Title:||Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging|
|Actual Study Start Date :||August 1, 2019|
Metformin alone has a significant impact on blood sugar levels. It is frequently a successful therapy when combined with physical activity, weight reduction, and perhaps additional drugs. It does not cause hypoglycemia and has no effect on weight gain or reduction. Metformin can be used by individuals with type 2 diabetes who are not able to use or tolerate other medications.
Bodybuilders have used metformin during cycles to help reduce fat accumulation. In one study, 12 obese men were given either 500 mg of metformin twice daily or a placebo for 16 weeks. The researchers found that those taking the drug lost more body fat and burned more calories than those on the placebo. They also required fewer minutes to reach their target heart rate during exercise testing. No side effects were reported by anyone in the trial.
More research is needed on the long-term effects of metformin when used by bodybuilders at typical doses. However, this medication appears to be safe when used in combination with other medications and methods for losing weight.